Targeted Development of Pyrazoline Derivatives for Neurological Disorders: A Review

Abstract

AbstractPyrazolines are preferred to be stable heterocycles in medication development. It has been established from previous research that the 2‐pyrazolone scaffold is a common pattern that can be found in many pharmacologically significant therapeutic compounds. They are said to have a wide range of biological actions and have been thoroughly investigated by the scientific community. 2‐pyrazoline has been used as an intriguing pharmacophore to create novel compounds with enhanced potency, less toxicity, and the necessary pharmacokinetic profile to treat unprecedented diseases and global drug resistance. Experiments done by docking confirmed the hypothesized neuropharmacological mode of action and demonstrated a strong affinity towards the monoamine oxidase, β‐amyloid plaques, and AChE. Furthermore, additional computational pharmacokinetic assessments signify that it may not have any significant risk of carcinogenic effects, neurotoxic effects, reproductive intoxication, acute toxicity, mutagenicity, or irritations suggesting their possible utility in depressive, convulsions, and anxiety disorders. This discussion outlines a reliable approach for medicinal chemists to develop pyrazolines for the establishment of neurodegenerative research as well as future research programs on neurodegenerative disorders.